Suppr超能文献

膜胆固醇调节内皮细胞中凝集素样氧化低密度脂蛋白受体1的脱落

Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells.

作者信息

Gioia Magda, Vindigni Giulia, Testa Barbara, Raniolo Sofia, Fasciglione Giovanni Francesco, Coletta Massimiliano, Biocca Silvia

机构信息

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.

出版信息

PLoS One. 2015 Oct 23;10(10):e0141270. doi: 10.1371/journal.pone.0141270. eCollection 2015.

Abstract

The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor responsible for ox-LDL recognition, binding and internalization, which is up-regulated during atherogenesis. Its activation triggers endothelium dysfunction and induces inflammation. A soluble form of LOX-1 has been identified in the human blood and its presence considered a biomarker of cardiovascular diseases. We recently showed that cholesterol-lowering drugs inhibit ox-LDL binding and internalization, rescuing the ox-LDL induced apoptotic phenotype in primary endothelial cells. Here we have investigated the molecular bases of human LOX-1 shedding by metalloproteinases and the role of cell membrane cholesterol on the regulation of this event by modulating its level with MβCD and statins. We report that membrane cholesterol affects the release of different forms of LOX-1 in cells transiently and stably expressing human LOX-1 and in a human endothelial cell line (EA.hy926). In particular, our data show that i) cholesterol depletion triggers the release of LOX-1 in exosomes as a full-length transmembrane isoform and as a truncated ectodomain soluble fragment (sLOX-1); ii) endothelial cells secrete a soluble metalloproteinase which induces LOX-1 ectodomain shedding and iii) long term statins treatment enhances sLOX-1 proteolytic shedding.

摘要

凝集素样氧化低密度脂蛋白受体1(LOX-1)是一种清道夫受体,负责氧化型低密度脂蛋白(ox-LDL)的识别、结合和内化,在动脉粥样硬化形成过程中其表达上调。它的激活会引发内皮功能障碍并诱导炎症。在人体血液中已鉴定出可溶性形式的LOX-1,其存在被认为是心血管疾病的生物标志物。我们最近发现,降胆固醇药物可抑制ox-LDL的结合和内化,挽救ox-LDL诱导的原代内皮细胞凋亡表型。在此,我们研究了金属蛋白酶介导的人LOX-1脱落的分子基础,以及通过用甲基-β-环糊精(MβCD)和他汀类药物调节细胞膜胆固醇水平,其对这一过程调节的作用。我们报告,膜胆固醇影响瞬时和稳定表达人LOX-1的细胞以及人内皮细胞系(EA.hy926)中不同形式LOX-1的释放。特别是,我们的数据表明:i)胆固醇耗竭会触发外泌体中全长跨膜异构体形式和截短的胞外域可溶性片段(sLOX-1)形式的LOX-1释放;ii)内皮细胞分泌一种可溶性金属蛋白酶,可诱导LOX-1胞外域脱落;iii)长期他汀类药物治疗会增强sLOX-1的蛋白水解性脱落。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0652/4619672/f6ed09169380/pone.0141270.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验